BLES Biochemicals Inc.   Report issue

For profit Phase 2 Phase 4
Founded: London ON Canada (1992)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2019
NCT04019106
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

BLES Biochemicals Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

surfactant (1 trial)

Drugs in Phase 2 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchopulmonary Dysplasia (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2